BI
BioGaia AB (publ)
BIOGY · OTC
$12.45 +0.00% (+$0.00)
1M +0.81%
Market Cap 12.0B kr
P/E Ratio 34.68x
Div. Yield 3.40%
ROE 27.53%
Bulios Fair Price
$11.1
10.8% downside
Current Price
$12.45
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BIOGY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
14 /100
Expensive P/E 34.68x
EV/EBITDA 24.42x
P/S 7.62x
Growth
36 /100
Stable EPS growth 3.84%
Rev. growth 11.69%
FCF growth 0.21%
Profitability
100 /100
Strong Gross margin 73.01%
Net margin 21.97%
Op. margin 28.10%
Quality
100 /100
Excellent ROIC 30.77%
ROE 27.53%
ROA 25.91%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 4.44x
Int. coverage 77.15x
Stability
83 /100
Stable Beta 0.32x
Rev. volatility 4.98%
EPS volatility 1.65%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BIOGY
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Theresa Agnew
Employees
242
Headquarters
Stockholm
Upcoming events
22 OCT
Earnings
Upcoming earnings report